Recent events
Recent events tied to this brand in public sources.
Back to profile76 entries · Page 4 of 4
2020
Merck introduces BrightLab
Merck introduced BrightLab, a cloud-based inventory management and instrument connectivity platform for research scientists.
2020
Merck reports fourth-quarter and full-year 2019 results
Merck reported worldwide sales of US$11.9 billion for the fourth quarter of 2019 in its fourth-quarter and full-year financial results.
2020
Merck subsidiary enters drug research and licensing deal with Taiho and Astex
Taiho Pharmaceutical said it entered a research and licensing deal with a Merck subsidiary and Astex Pharmaceuticals to develop drugs against various targets, including KRAS. The deal includes a $50 million upfront payment for Taiho and Astex and up to $2.5 billion in milestones.
2019
FDA approves Merck's ERVEBO Ebola vaccine
The article reports that Merck received FDA approval for its Ebola vaccine, marketed as ERVEBO, on December 20, 2019.
2019
FDA approves Merck’s Ervebo Ebola vaccine
Merck announced that the FDA had approved its Ebola vaccine, Ervebo.
2019
Prasco launches authorized generic of NuvaRing
Prasco announced the launch of an authorized generic of NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) in the United States.
2019
Merck and Ping An Good Doctor sign strategic partnership
Merck and Ping An Good Doctor signed a strategic cooperation agreement in Shanghai to explore integrated solutions in China and advance smart healthcare.
2019
Merck wins R&D 100 Award for Eshmuno CP-FT Resin
Merck received an R&D 100 Award for its Eshmuno CP-FT Resin, a product used in biopharmaceutical manufacturing.
2019
Merck KGaA raises 2019 sales and earnings guidance
Merck KGaA raised its full-year 2019 sales and adjusted earnings forecast after completing its takeover of Versum Materials in October.
2019
Merck acquires Calporta
Merck acquired San Diego-based Calporta, expanding its activity in neurodegeneration research. The article reports potential total consideration of up to $576 million, including an undisclosed upfront payment and contingent milestone payments.
2019
Merck agrees to acquire Calporta
Merck agreed to acquire Calporta, a developer of treatments for neurodegenerative and lysosomal storage disorders, for up to $576 million, including an upfront payment and milestone-based payments. The announcement did not detail those payments.
2019
FlexEnable acquires Merck’s OTFT material intellectual property
FlexEnable acquired Merck’s OTFT material intellectual property, including patents, expertise and the related materials supply chain. The acquired materials were renamed FlexEnable FlexiOM.
2019
Merck completes acquisition of Versum Materials
Merck announced that it had closed its transaction to acquire Versum Materials for approximately €5.8 billion, making Merck the sole owner of Versum.
2019
GSK announces planned INDUCE-3 trial
GlaxoSmithKline announced that it would support a planned Phase II/III trial combining GSK3359609 with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma. The trial was planned to start by the end of 2019.
2019
Merck completes acquisition of Intermolecular
Merck completed its acquisition of Intermolecular, a California-based advanced materials innovation company. Upon closing, approximately 90 Intermolecular employees at its San Jose research and development site became part of Merck’s Performance Materials business sector.
2017
Merck settles PD-1 patent litigation with BMS and Ono
Merck agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625 million and royalties on Keytruda sales to settle patent infringement litigation concerning PD-1 inhibitors. The agreement provided for dismissal of the patent litigation filed against Merck.